FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, specifically to multi-specific proteins; it can be used in medicine. The invention makes it possible to obtain a molecule of a substance containing more than one immunoglobulin variable domain (ISVD) or nano-bodies and capable of specific binding to both PD1 and CTLA4. The structure of such proteins allows reducing the frequency of binding by natural antibodies in the subject’s body.
EFFECT: invention can be used in the preparation of a drug to increase an immune response in a subject, as well as in the treatment of various malignant tumors and/or the treatment of infectious diseases.
25 cl, 17 dwg, 12 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ADVANCED SERUM ALBUMIN BINDING AGENTS | 2018 |
|
RU2797270C2 |
| IMPROVED SINGLE VARIABLE IMMUNOGLOBULIN DOMAINS BINDING TO SERUM ALBUMIN | 2017 |
|
RU2765384C2 |
| IMPROVED SUBSTANCES BINDING TO SERUM ALBUMIN | 2018 |
|
RU2789495C2 |
| POLYPEPTIDES BINDING TO ADAMTS5, MMP13, AND AGGRECAN | 2018 |
|
RU2786659C2 |
| MMP13-BINDING IMMUNOGLOBULINS | 2018 |
|
RU2784069C2 |
| ADAMTS-BINDING IMMUNOGLOBULINS | 2018 |
|
RU2781182C2 |
| IMPROVED TNF-BINDING AGENTS | 2016 |
|
RU2774823C2 |
| IMPROVED VARIABLE DOMAINS OF IMMUNOGLOBULINS | 2015 |
|
RU2746738C2 |
| IMPROVED IMMUNOGLOBULIN VARIABLE DOMAINS | 2015 |
|
RU2809788C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
